Maegim한국어

코미팜

041960KOSDAQSector: Pharma & Biotech
₩7,080 1.14%Market cap ₩523.1BAs of Jul 21, 2026 close · updated once daily
C
Grade C41.3 ptsTop 69% of 2,523 stocks
Financial strength
44.3
Growth momentum
47.0
Price attractiveness
33.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

44.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
85.8%
Below median · Top 69.7% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
129.8%
Below median · Top 63.6% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
3.7%
Above median · Top 33.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-10.4%
Below median · Top 56.3% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

47.0
How much did revenue grow in a year?
Revenue growth (YoY)
-10.7%
Below median · Top 82% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
9.6%
Above median · Top 33.8% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-68.3%
Below median · Top 86.4% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
151.5%
Above median · Top 9.9% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

33.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Above median · Top 49.4% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
7.52x
Below median · Top 83.1% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15